43 results about "Postmenopausal osteoporosis" patented technology

The invention relates to the technical field of data processing, and discloses a postmenopausal osteoporosis risk assessment system based on big data, a data preprocessing module is used for collecting multidimensional data of postmenopausal women and processing the collected data to obtain preprocessed data; the feature extraction module is used for extracting features related to the postmenopausal osteoporosis risk from the preprocessed data to obtain target feature data; the risk assessment module is used for constructing a risk assessment model based on the target feature data, inputting the original data of the to-be-assessed postmenopausal female into the risk assessment model after data preprocessing and feature extraction, and outputting a risk assessment result of osteoporosis of the to-be-assessed female; the result visualization module is used for visualizing the risk assessment result and providing corresponding intervention suggestions according to different risk levels; according to the invention, early prevention and intervention of postmenopausal osteoporosis can be realized.

The invention discloses a humanized osteoporosis mouse model and a construction method thereof, and belongs to the technical field of biotechnology and animal models. The invention aims at the core defects of large species difference, insufficient humanization degree, low pathological simulation degree, unstable phenotype and the like of the existing osteoporosis model. The humanized osteoporosis mouse model is constructed through five core steps of experimental animal pretreatment, collagen-nano hydroxyapatite bionic scaffold preparation and cell pre-implantation, immune-bone metabolism double-derived system construction, progressive osteoporosis induction and model identification and verification. According to the method, double-person origination of immune and bone metabolism systems is realized for the first time, the colonization rate and survival time of human cells are greatly improved, the pathological process of clinical postmenopausal osteoporosis is accurately simulated, the phenotype of the model is stable and uniform, the reactivity matching degree with clinical drugs is high, and the method can be widely applied to research and development of anti-osteoporosis drugs and research of pathological mechanisms.

The invention relates to the field of disease animal model construction, and particularly discloses a postmenopausal osteoporosis and knee osteoarthritis co-disease animal model construction method which comprises the following steps: selecting a female animal as an experimental subject; the selected female animals are injected with a GnRH agonist, meanwhile, low-calcium feed feeding and oxidative stress stimulation are conducted, and feeding is conducted for a preset time; detecting bone mineral density and bone trabecula parameters of the fed female animals, and screening qualified female animals meeting set standards; performing meniscus tearing operation on the qualified female animal, and implanting sustained release microspheres loaded with inflammatory factors at the torn part during the operation; carrying out weight-bearing training on the female animal after the operation, and continuing for a set time length; and performing health detection on the female animals at different time points. According to the method, through multi-factor collaborative induction of the PMOP, minimally invasive construction of the KOA and multi-dimensional health detection, accurate simulation of a co-disease pathological process and clinical characteristics is realized, and the authenticity and stability of the model are improved.

The invention relates to the technical field of medical preparations, and particularly discloses a selenium-based anti-postmenopausal osteoporosis medicine and a preparation method and application thereof.The selenium-based anti-postmenopausal osteoporosis medicine comprises a main active component, a secondary active component and an auxiliary active component, the main active component is a nano-selenium-phytoestrogen compound and is formed by covalent coupling of selenomethionine and soy isoflavone, the particle size of the main active component is 50-200 nm, and the particle size of the auxiliary active component is 100-200 nm; the mass of the selenium element accounts for 5-30% of the mass of the compound; the auxiliary active component is a collagen peptide-calcium chelate and is prepared from marine collagen peptide and calcium citrate through chelation reaction, and the mass ratio of the calcium element to the collagen peptide is (1: 3)-(1: 5); the targeted delivery carrier is folic acid modified chitosan nanoparticles and is used for loading the main active component and the auxiliary active component; the auxiliary materials comprise a disintegrating agent, a lubricating agent and a pH-sensitive enteric coating material; through the synergistic effect of the main active ingredient nano-selenium-phytoestrogen compound and the auxiliary active ingredient collagen peptide-calcium chelate, bone formation can be promoted and bone resorption can be inhibited at the same time, and dual-function treatment is achieved.

The invention relates to sRNA, a composition and application of the sRNA and the composition, and belongs to the field of medicinal small nucleic acid. According to the sRNA provided by the invention, the expression quantity is reduced by targeting a specific sequence of mRNA of a sclerostin gene SOST, so that the expression quantity or activity of an alkaline phosphatase gene is improved to promote osteoblast differentiation and further prevent, treat or improve bone metabolic diseases such as osteoporosis, and the sRNA is particularly suitable for treating postmenopausal osteoporosis or senile osteoporosis.

The invention provides an application of miR-337 in preparation of a medicine for treating osteoporosis, which is used for the medicine for treating osteoporosis, and relates to the technical field of biomedicine. The research of the inventor finds that miR-337 can activate p53 to promote apoptosis of osteoclasts, has a certain treatment effect on osteoporosis, and can be used for preparing the medicine for treating osteoporosis; the nano vesicles derived from human umbilical cord mesenchymal stem cells have certain anti-inflammatory activity and have a positive effect on treatment of osteoporosis. According to the application disclosed by the invention, miR-337 is further loaded on nano vesicles derived from human umbilical cord mesenchymal stem cells, and the research of the inventor finds that the medicine has a good treatment effect on osteoporosis, provides a new strategy for preventing postmenopausal osteoporosis, and has remarkable clinical transformation potential.

The invention provides a self-supplementing metabolism-enhanced synbiotic microsphere and preparation and application thereof, and belongs to the technical field of microbial medical preparations. Cyclopentadienyl norbornene hyaluronic acid (HA-NOR) and sulfhydrylation hyaluronic acid (HA-SH) are combined through thiol-ene click reaction, lactobacillus rhamnosus LGG is used as an active metabolism ecological niche, hyaluronic acid (HA) is used as an innovative prebiotic matrix capable of achieving self-supplementing, and the self-supplementing prebiotic composition is prepared. And the self-supplementing metabolism-enhanced synbiotics microspheres (SMASMs) are successfully prepared, so that the intestinal tract-skeleton metabolic balance is recovered. As a prebiotic preparation capable of enhancing metabolism, the oral microspheres disclosed by the invention can efficiently utilize probiotics to realize intestinal flora regulation and promote generation and metabolism of short-chain fatty acid, and can synergistically reconstruct intestinal-bone homeostasis by down-regulating an osteoclast signal channel, so that a patient with postmenopausal osteoporosis can be better treated; and the medicine curative effect is efficiently exerted through oral administration.

The invention discloses a telmisartan glucoside derivative, a microbial conversion preparation method thereof and application of the telmisartan glucoside derivative in preparation of a medicine for preventing or treating osteoporosis. The telmisartan glucoside derivative is characterized in that a telmisartan propyl side chain is connected with a glucosyl group. According to the invention, a microbial conversion technology is utilized, telmisartan is taken as a substrate, and glucosyl is introduced into a telmisartan propyl side chain in a regioselective manner, so that the telmisartan glucoside derivative with a novel structure is obtained. Experiments on the osteoblast proliferation promoting activity and the postmenopausal osteoporosis resisting effect of the telmisartan glucoside derivative by using an in-vitro osteoblast model and an ovariectomized induced osteoporosis mouse model prove that the telmisartan glucoside derivative has relatively good osteoblast proliferation promoting activity and postmenopausal osteoporosis resisting activity; the compound can be used as an active component of a medicine for treating osteoporosis, and has wide application.

The present application relates to the technical field of medicine, and more particularly to the application of beta-hydroxybutyric acid in the preparation of a drug for preventing and / or treating osteoporosis, including postmenopausal osteoporosis due to estrogen deficiency and diabetic osteoporosis, wherein the concentration of the beta-hydroxybutyric acid is 150 mM, the application of beta-hydroxybutyric acid in the preparation of a drug for inhibiting the differentiation of osteoclasts or inhibiting the formation of osteoclasts, wherein the beta-hydroxybutyric acid inhibits the differentiation of osteoclast precursor cells into osteoclasts, and the concentration of the beta-hydroxybutyric acid is 10 mM; the present application proves that beta-hydroxybutyric acid improves the bone microstructure of OVX mice and db / db mice, inhibits the differentiation of osteoclasts, and reduces bone resorption, thereby providing a new target for the prevention and treatment of osteoporosis.

The invention relates to the technical field of biological medicines, in particular to application of pyrimido pyrazole derivatives in treatment of postmenopausal osteoporosis. The pyrimido pyrazole derivative is a derivative as shown in a formula I or a pharmaceutically acceptable salt thereof. Wherein R1 is as described in the claims and the specification. The pyridinopyrazole derivative is a derivative shown in a formula I or a pharmaceutically acceptable salt thereof, and can be used for preparing a medicine for treating and / or preventing osteoporosis, especially postmenopausal osteoporosis. # imgabs0 #

The invention discloses application of a let-7e inhibitor loaded on nano-vesicles derived from bone marrow mesenchymal stem cells in preventive treatment of postmenopausal osteoporosis, and belongs to the technical field of biological medicines. According to the invention, the let-7e inhibitor is designed and synthesized and is'neutralized ', so that the inhibition of the let-7e inhibitor on an osteogenic gene is relieved, the osteogenic function of osteoblasts is promoted, and meanwhile, the nano-vesicles which are derived from mesenchymal cells and have an anti-inflammatory effect are selected as a delivery tool of the let-7e inhibitor to prevent and treat osteoporosis. Experimental results indicate that the mouse bone marrow mesenchymal stem cell-derived nano-vesicle loaded with the let-7e inhibitor has a good preventive treatment effect on mouse osteoporosis after ovariectomy. A stem cell nano-vesicle treatment platform based on mouse bone marrow mesenchymal stem cell-derived nano-vesicles loaded with let-7e inhibitors is expected to be developed into a novel clinical intervention scheme for preventing postmenopausal osteoporosis.

The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.

The invention discloses a compound traditional Chinese medicine preparation for treating postmenopausal osteoporosis, osteoarthritis and / or premature ovarian insufficiency as well as a preparation method and application of the compound traditional Chinese medicine preparation, and belongs to the technical field of traditional Chinese medicines. The compound traditional Chinese medicine preparation is prepared from the following components: 10 to 30 g of radix rehmanniae preparata, 10 to 30 g of radix angelicae sinensis, 8 to 15 g of rhizoma chuanxiong, 8 to 15 g of radix paeoniae alba, 10 to 30 g of radix codonopsis, 8 to 15 g of rhizoma atractylodis macrocephalae, 10 to 30 g of poria cocos, 5 to 10 g of liquorice root, 10 to 30 g of radix dipsaci, 8 to 15 g of radix achyranthis bidentatae, 8 to 15 g of fructus chaenomelis lagenariae, the compound traditional Chinese medicine preparation provided by the invention realizes effective treatment on osteoporosis, osteoarthritis and early-onset ovarian insufficiency, overcomes various defects of an existing treatment method, remarkably improves the treatment effect, reduces the side effects of medicines, and brings a new treatment choice for patients. And a new thought and a new method are expected to be provided for solving the treatment problem of the three diseases.

This invention discloses the application of an inhibitor of transcription factor C / EBPβ in the preparation of a drug for treating postmenopausal osteoporosis. This invention also discloses the application of transcription factor C / EBPβ in screening drugs that reduce postmenopausal FSH levels, wherein the drugs inhibit the expression of transcription factor C / EBPβ. Furthermore, this invention discloses the application of compounds #11a and CF3CN in the preparation of a drug for treating postmenopausal osteoporosis. This invention reveals for the first time that the C / EBPβ-AEP pathway participates in promoting FSHβ synthesis in a menopausal model. By reducing the transcription factor activity of C / EBPβ, it can reduce FSH expression at the pituitary gland, promote osteogenic differentiation, inhibit osteoclast resorption, and effectively alleviate PMOP symptoms. Compounds #11a and CF3CN can effectively achieve both anti-bone resorption and bone formation-promoting functions, achieving coupled treatment of PMOP.

The invention relates to the technical field of health risk assessment, in particular to a postmenopausal osteoporosis risk prediction and traditional Chinese and western medicine intervention management system. The system quantifies the trend risk of the bone mineral density through the deviation change of the bone mineral density risk value in time sequence, and combines the initial bone mineral density risk to divide the group and analyze and identify the risk degree of the group; coupling the drop fluctuation characteristics of hormones with the change of bone metabolism markers to obtain the comprehensive metabolic risk influence degree; determining the comprehensive influence degree of osteoporosis by utilizing the group comprehensive bone mineral density risk degree dynamic adjustment and combining the external risk influence degree and the comprehensive metabolic risk influence degree; and based on the osteoporosis comprehensive influence degree of the sample data, training a neural network model to carry out risk prediction. According to the method, the risk model is constructed by considering the multi-dimensional influence of hormone metabolism and behavioral habits of the postmenopausal patient and the multi-dimensional coupling evaluation value, so that the risk prediction accuracy is improved, and more comprehensive and reliable data support is provided for bone health management of postmenopausal women.

The invention discloses an application of a polypeptide as a marker in diagnosis of postmenopausal osteoporosis. The polypeptide is selected from at least one of peptide fragments P2 to P4. Wherein the peptide fragment P2 has an amino acid sequence as shown in SEQ ID NO. 6; the peptide fragment P3 has an amino acid sequence as shown in SEQ ID NO.7; and the peptide fragment P4 has an amino acid sequence as shown in SEQ ID NO.8. Peptide fragments specifically recognized by OP patient serum IgG are screened and identified on the basis of a phage immunoprecipitation sequencing technology, so that peptide fragments P2-P4 are obtained, and it is verified that the peptide fragments P2-P4 can serve as markers to diagnose osteoporosis. It is further verified that the AUC value of the peptide fragment P2 and the peptide fragment P4 for combined diagnosis of osteoporosis can reach 0.920, the AUC value of the peptide fragment P2 and the peptide fragment P4 for combined diagnosis of postmenopausal osteoporosis can reach 0.958, and the peptide fragment P2 and the peptide fragment P4 have very high diagnosis efficacy.

The invention discloses a CB2R / ER alpha double-target agonist and an application thereof. The invention finds that an endocannabinoid signal system interacts with an estrogen receptor, and the endocannabinoid signal system and the estrogen receptor are closely associated with osteoporosis which can cause reduction of protein expression of CB2R and ERalpha receptors. Animal experiments carried out by a CB2 and ER alpha receptor double-target agonist cimicifuic acid F prove that the composition has a remarkable effect of inhibiting osteoclast bone resorption in ovariectomized model mice and beta-galactose induced senescent mice; the compound can be used for improving the activity of ERalpha and influencing the activity of CB2R at the same time, has a double-target synergistic effect, can be used for patients with postmenopausal osteoporosis, and can also be used for preventing / treating diseases such as senile osteoporosis and the like.

This invention provides the application of Neoruscogenin in the preparation of anti-osteoporosis drugs, belonging to the field of pharmaceutical biotechnology. It was found that Neoruscogenin can significantly increase bone volume fraction, bone surface area to tissue volume ratio, bone mineral density, trabecular bone number, and trabecular bone thickness in osteoporotic mice, while significantly reducing trabecular bone separation; that is, Neoruscogenin can alleviate low bone mass in postmenopausal osteoporotic mice. Furthermore, Neoruscogenin treatment for 8 weeks did not significantly affect the major organs of mice, suggesting the biocompatibility of Neoruscogenin.

The invention discloses a bone-targeted functionalized tetrahedral framework nucleic acid nano system as well as a preparation method and application thereof, the bone-targeted functionalized tetrahedral framework nucleic acid nano system comprises tetrahedral framework nucleic acid tFNA-Sa, polypeptide SDSSD with bone cell specific targeting and an osteoporosis treatment drug, the bone targeting tetrahedral framework nucleic acid tFNA-Sa is used for modifying bone targeting polypeptide to obtain the bone targeting tetrahedral framework nucleic acid tFNAs-SDSSD, the editability and the biocompatibility of the nucleic acid tetrahedron are utilized, the SDSSD bone targeting peptide is modified on the surface of the tetrahedron, the bone targeting ability can be given to the bone targeting peptide, and then the purposes of efficient aggregation of the medicine in bone tissue, high-efficiency drug delivery and the like are achieved. The distribution of the medicine in non-target tissues is reduced. The targeted delivery system not only can improve the treatment effect of the medicine, but also can greatly reduce the side effect of the medicine, and brings a new scheme for targeted therapy for postmenopausal osteoporosis.

The present application relates to the application of Radix Rehmanniae Preparata polysaccharide in postmenopausal osteoporosis, and relates to the application of active ingredients of traditional Chinese medicine in the treatment of bone metabolism diseases. The Radix Rehmanniae Preparata polysaccharide can improve the postmenopausal osteoporosis by up-regulating the expression of estrogen receptors and promoting the synthesis of estrogen.

The invention relates to application of a TXNIP specific inhibitor in preparation of a product for preventing and treating osteoporosis or fracture. The product is a composition or preparation containing SRI-37330 or an optical isomer thereof, or pharmaceutically acceptable salt thereof. Compared with the prior art, it is found that SRI-37330 can efficiently and specifically reduce the level of TXNIP protein in osteogenesis and osteoclast and inhibit differentiation of osteogenesis and osteoclast, and therefore the SRI-37330 has the functions of promoting bone metabolism to enter low conversion so as to prevent and treat diabetic osteoporosis, fracture and postmenopausal osteoporosis. The invention proves that the SRI-37330 has an active ingredient capable of safely and effectively promoting bone metabolism to enter low conversion so as to prevent and treat diabetic osteoporosis, fracture and postmenopausal osteoporosis.

This invention provides an application of the PDK4 gene, which is used to prepare drugs to improve postmenopausal osteoporosis. PDK4 gene deletion in bone marrow mesenchymal stem cells (BMSCs) reduces their osteogenic differentiation capacity and inhibits mitochondrial division by blocking the E2-DRP1 signaling axis. Overexpression in bone tissue reverses bone formation inhibition caused by postmenopausal osteoporosis. This invention redefines the biological function of the PDK4 gene in the skeletal system. This gene promotes osteogenic differentiation of BMSCs through the E2-ERα-PDK4-MYH9-DRP1 signaling axis, thus improving postmenopausal osteoporosis and providing a new theoretical framework and potential target for developing bone-promoting therapies for postmenopausal osteoporosis.

The invention discloses a preparation method and application of soybean-sourced nano phytoestrogen nano vesicles, belongs to the technical field of biological nano materials, solves the technical problems of poor bone targeting ability and low bioavailability of supplemented exogenous estrogens, and comprises the following steps: S1, weighing, cleaning and soaking; s2, crushing and filtering; s3, performing differential centrifugation; s4, performing extrusion to obtain nano phytoestrogen nano vesicles (SVs) from soybeans, and storing the nano phytoestrogen nano vesicles (SVs) at-80 DEG C for later use; the prepared SVs are applied to preparation of medicines for treating postmenopausal osteoporosis diseases. The soybean-sourced phytoestrogen nano-vesicle prepared by combining a differential centrifugation method with an extrusion method is wide in raw material source and simple in extraction process, is used as a plant estrogen, is rich in various bioactive components such as proteins, lipids and isoflavonoids, reverses the state of bone resorption and bone formation imbalance under the estrogen deficiency state, and has a good application prospect. And a new solution is provided for the treatment of postmenopausal osteoporosis.

The invention discloses the application of the Chinese wolfberry fruit-glossy privet fruit and calcitriol composition in the medicine for treating postmenopausal osteoporosis for the first time, and through three-layer research of'in vitro cell-animal model-molecular pathway ', it is clear that the composition can bidirectionally regulate and control kidney vitamin D metabolic enzyme by activating'PI3K-AKT' signal pathway for the first time, so that the curative effect on postmenopausal osteoporosis is achieved. Further, the serum 25 hydroxyl vitamin D and blood calcium level are improved, and the bone mineral density is improved. The mechanism provides a modern molecular biology support for the traditional Chinese medicine theory of'kidney dominating bone ', and also establishes a new path of'regulating kidney metabolic enzyme to treat osteoporosis'. By optimizing the metabolic bone protection effect of the vitamin D, bone loss of ovariectomized mice is effectively delayed, meanwhile, the vitamin D and calcitriol play a synergistic effect, and the vitamin D has a multi-target bone protection effect in postmenopausal PMOP, has anti-osteoporosis activity and can be used for treating the PMOP.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a kidney-tonifying and liver-nourishing compound preparation in preparation of a medicine for improving postmenopausal osteoporosis, and the kidney-tonifying and liver-nourishing compound preparation comprises the following components in parts by weight: 5-15 parts of roasted herba epimedii, 5-15 parts of fructus cnidii, 50-70 parts of roasted astragalus membranaceus and 10-30 parts of dogwood. Experiments show that the kidney-tonifying and liver-nourishing compound preparation can improve the problems of gap enlargement and structure looseness of bone tissue morphology and can inhibit bone loss, namely, the kidney-tonifying and liver-nourishing compound preparation has the effect of improving postmenopausal osteoporosis; compared with a traditional estrogen replacement therapy, the kidney-tonifying and liver-nourishing compound preparation has the advantages that the side effects are obviously reduced, the safety is improved, and a foundation is laid for developing safe and effective anti-osteoporosis medicines in the future.

The application discloses application of a medicine, miltefosine, in promoting bone formation and preventing and treating osteoporosis. In the bone formation process, the expression of protein phosphatase PPM1A in osteoblasts is significantly increased, the dephosphorylation of a core protein Smad2 of a TGF-beta signal path is regulated, the TGF-beta signal path is inhibited, the expression of an osteogenic marker is promoted, and the osteogenic ability of the organism is enhanced. The application discloses that the medicine, miltefosine, is used as a PPM1A enzyme activity catalyst, the in-vivo intervention of the medicine can significantly accelerate bone repair and delay bone loss of postmenopausal osteoporosis, a mechanism is that the enzyme activity of PPM1A of osteoblasts is catalyzed, the dephosphorylation of Smad2 protein is promoted, the TGF-beta / Smad2 signal path activity is inhibited, bone formation is promoted, bone repair is accelerated, and bone loss is prevented. Therefore, the miltefosine has a good application prospect in clinical treatment of promoting osteogenesis and preventing and treating osteoporosis.

This invention discloses the use of CPT2 inhibitors in the treatment of postmenopausal osteoporosis. By detecting fatty acid oxidation levels in osteoclast precursor cells and CPT2 expression levels, postmenopausal osteoporosis can be predicted. It also discloses the use of CPT2 as a diagnostic marker for postmenopausal osteoporosis. The CPT2 inhibitors include perhexiline maleate, among others. This invention reveals a new use of CPT2 as a marker and therapeutic target for postmenopausal osteoporosis, providing important evidence for the clinical application of CPT2 inhibitors.

The invention relates to the technical field of pharmaceutical preparations, in particular to a pharmaceutical composition for treating osteoporosis, a preparation and a preparation method and application thereof. The medicine composition is prepared from the following medicinal materials in parts by weight: 5 to 10 parts of herba epimedii, 10 to 15 parts of tortoise plastron, 6 to 12 parts of rhizoma anemarrhenae, 10 to 15 parts of radix rehmanniae recen, 10 to 15 parts of radix astragali, 6 to 12 parts of herba dendrobii, 6 to 12 parts of radix curcumae, 6 to 12 parts of rhizoma cyperi, 10 to 15 parts of semen cuscutae, 3 to 8 parts of colla corii asini, 10 to 15 parts of caulis spatholobi, 6 to 12 parts of cortex phellodendri, 10 to 15 parts of rhizoma drynariae and 10 to 15 parts of radix dipsaci. According to the present invention, the pathogenesis of the postmenopausal osteoporosis is deeply analyzed, the corresponding treatment method and the corresponding treatment rule are formulated according to the pathogenesis, the unique compatibility relationship between the compositions is finally formed, and the new osteoporosis treatment pharmaceutical composition is provided, is the pure traditional Chinese medicine preparation, has characteristics of no significant toxic-side effect, no side effect, no toxic-side effect, and no side effect, and can be used for treating the postmenopausal osteoporosis. Animal experiments prove that the traditional Chinese medicine preparation has a remarkable curative effect on postmenopausal osteoporosis.

The invention belongs to the technical field of biological medicines, and particularly discloses application of a lipophage receptor protein SPARTIN overexpressed adenovirus in preparation of a medicine for preventing and treating postmenopausal osteoporosis, after a lipophage receptor protein SPARTIN gene is inserted into a PLVX lentiviral vector to construct a transfection plasmid, the transfection plasmid and virus component expression plasmids PxpaX2 and PMD2G are co-transfected in an HEK 293T cell, after 48 hours, a virus supernatant is collected, and the recombinant adenovirus is obtained. The amino acid sequence of the SPARTIN protein gene is as shown in SEQ ID NO. 1. The invention also discloses a preparation method of the SPARTIN overexpressed adenovirus. Compared with the prior art, overexpression of the lipophage receptor protein SPARTIN can supplement expression of cell lipophage receptor protein, enhance marrow lipolysis and promote bone formation, so that the purpose of treating postmenopausal osteoporosis is achieved. And finally, compared with the existing lentivirus / adenovirus therapy, the BMAs targeting property is higher, and the BMAs targeting agent is safer and more effective.

The invention discloses application of a CPT2 inhibitor in treatment of postmenopausal osteoporosis, and the postmenopausal osteoporosis can be predicted by detecting the fatty acid oxidation level of osteoclast precursor cells and the expression level of CPT2; the invention further discloses an application of the CPT2 serving as a diagnostic marker of the postmenopausal osteoporosis, and a CPT2 inhibitor comprises Perhexiline maleate and the like. The invention discloses a new application of CPT2 as a postmenopausal osteoporosis marker and a therapeutic target, and provides an important basis for clinical transformation of a CPT2 inhibitor.